MicroRNA in Human Malignancies

MicroRNA in Human Malignancies

1st Edition - February 17, 2022

Write a review

  • Editors: Massimo Negrini, George Calin, Carlo Croce
  • Paperback ISBN: 9780128222874
  • eBook ISBN: 9780128232743

Purchase options

Purchase options
Available
DRM-free (PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

MicroRNA in Human Malignancies offers a deep overview of the role and translational significance of miRNAs in the development of cancer and other malignancies. The book establishes the foundations of the field by covering essential mechanisms and the translational potential of miRNAs in the field of oncology. Specific topics covered include invasion and metastasis, miRNAs and metabolism, and opportunities of miRNAs in therapeutics. Chapters on diseases include content on disease-related pathophysiology, as well as diagnostic, prognostic and predictive value. This book is an essential reference for students entering the field, as well as researchers and investigators.

Key Features

  • Provides fundamental and translational chapters that facilitate the acquisition of knowledge needed to design and perform innovative miRNA-related research studies
  • Synthesizes current research, with a critical review on the field
  • Offers in-depth research by leading experts in the field

Readership

Students and researchers across the biosciences and the biomedical sciences and biotechnology fields; investigators and medical oncologists interested in both basic and translational research

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Contributors
  • Section A: miRNAs involvement in basic mechanisms of cancer development
  • Chapter 1: Overview on miRNA classification, biogenesis, and functions
  • Abstract
  • Introduction
  • MicroRNA and the complex biological system of gene expression
  • MicroRNA biogenesis, nomenclature, and classification
  • Mechanisms of miRNA-mediated gene regulation
  • Concluding remarks
  • References
  • Chapter 2: microRNA in cancer: An overview
  • Abstract
  • The dawn of miRNAs in human biology
  • First reported miRNA cancer-associated alterations
  • The age of discovery: Microarrays and miRNA cancer signatures
  • Functional classification of miRNA: The line between tumor suppressor and oncomiRs
  • Development of miRNA as biomarkers
  • The transition of miRNA into clinics
  • Conclusion and future perspectives
  • References
  • Chapter 3: miR-15/16 in human malignancies
  • Abstract
  • 13q deletions in CLL and miR-15/16
  • Other mechanisms of miR-15/16 dysregulation
  • Interplay between ROR1, Bcl2, and miR-15/16 in CLL
  • miR-15/16 in mice
  • miR-15/16 in human AML and MDS
  • miR-15/16 in solid cancers
  • References
  • Chapter 4: microRNAs and tumor suppressor p53 regulation
  • Abstract
  • p53 and its signaling pathway
  • GOF mutant p53 in cancer
  • miRNAs regulated by wild-type p53
  • miRNAs that directly regulate p53
  • miRNAs that indirectly regulate p53
  • miRNAs regulated by GOF mutp53
  • Conclusion
  • References
  • Chapter 5: MicroRNA involvement in invasion and metastasis
  • Abstract
  • Acknowledgment
  • Introduction—The process of metastasis
  • Direct regulation of metastasis
  • Indirect regulation of metastasis
  • Translational application of metastasis-associated miRNAs
  • Conclusions and perspectives
  • References
  • Chapter 6: microRNAs and metabolism
  • Abstract
  • Introduction
  • Trafficking and consumption of glucose
  • NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways
  • PI3K/Akt/mTOR and HIF-1 signaling pathway
  • p53 signaling pathway
  • Conclusion and future perspectives
  • References
  • Chapter 7: microRNAs in inflammation processes
  • Abstract
  • Introduction
  • MiRNA biogenesis and functions
  • Inflammation and mechanism of activation
  • miRNAs in inflammatory disease
  • Conclusion
  • References
  • Section B: miRNAs methodologies
  • Chapter 8: Wet-lab methods for miRNA analysis
  • Abstract
  • Acknowledgments
  • Introduction
  • Methods for miRNA discovery and detection
  • Functional miRNA analysis
  • Final remarks
  • References
  • Chapter 9: Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks
  • Abstract
  • Acknowledgments
  • Introduction
  • Target prediction algorithms
  • In silico functional assessment of miRNAs: Tips and tricks
  • Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case
  • Conclusions
  • References
  • Chapter 10: Computational resources for analysis of miRNA targetome
  • Abstract
  • Introduction
  • miRNA target databases
  • miRNA algorithms
  • Conclusion
  • References
  • Chapter 11: miRNA bioinformatics and pathway analysis
  • Abstract
  • The microRNA synergy
  • Role of microRNAs in biological signaling pathways
  • Pathways: The manually curated maps of the cell interactome
  • The miRNA interactome
  • miRNA pathway analysis methods
  • Conclusions
  • References
  • Section C: miRNAs involvement in therapeutics/ theranostics
  • Chapter 12: Opportunities of miRNAs in cancer therapeutics
  • Abstract
  • Introduction
  • MicroRNA-based drug design
  • MicroRNA-based therapeutics in the current clinic
  • The future of miRNAs in the clinic
  • References
  • Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities
  • Chapter 13: Pathophysiology roles and translational opportunities of miRNAs in acute leukemias
  • Abstract
  • Introduction
  • MiRNAs involved in the pathogenesis of AML
  • miRNAs as biomarkers
  • miRNAs in chemoresistance
  • miRNAs as therapeutic targets
  • Role of miR-15/16 clusters in AML pathogenesis
  • Conclusions
  • References
  • Chapter 14: Pathophysiology roles and translational opportunities of miRNAs in CLL
  • Abstract
  • MicroRNAs and the cellular origin of CLL cells
  • MicroRNAs and CLL genetics
  • microRNAs in proliferation and survival of CLL cells
  • microRNAs and BCR signaling
  • MicroRNAs and microenvironment
  • MicroRNAs and apoptosis
  • Translational opportunities
  • References
  • Chapter 15: Pathophysiology roles and translational opportunities of miRNAs in lymphoma
  • Abstract
  • Summary
  • miRNAs and pathophysiology
  • miRNAs regulate the expression of genes that promote B-cell differentiation
  • References
  • Chapter 16: Pathophysiology rolesr and translational opportunities of miRNAs in breast cancer
  • Abstract
  • Breast physiology and pathology
  • MicroRNAs in breast physiology
  • MicroRNAs in breast cancer
  • Conclusions
  • References
  • Chapter 17: Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer
  • Abstract
  • Introduction
  • Involvement of miRNAs in the pathophysiology of CRC
  • The interconnection between miRNAs and epigenetics in CRC
  • Translational opportunities of miRNAs in CRC
  • Perspectives and future challenges
  • Funding
  • References
  • Chapter 18: Pathophysiology roles and translational opportunities of miRNAs in lung cancer
  • Abstract
  • Pathophysiology
  • Tissutal miRNAs as diagnostic or prognostic biomarkers
  • Circulating miRNAs
  • References
  • Chapter 19: Pathophysiology roles and translational opportunities of miRNAs in mesothelioma
  • Abstract
  • Introduction
  • miRNAs as biomarkers for MPM diagnosis
  • miRNAs as biomarkers for malignant pleural mesothelioma prognosis
  • Contribution of miRNAs in drug MPM resistance
  • Therapeutic role of miRNAs
  • Conclusion and future perspectives
  • References
  • Chapter 20: Pathophysiology roles and translational opportunities of miRNAs in renal cancer
  • Abstract
  • Introduction
  • Pathophysiology
  • Diagnostic, prognostic, and predictive value
  • Circulating miRNAs
  • Conclusions
  • References
  • Chapter 21: Pathophysiology roles and translational opportunities of miRNAs in pancreatic cancer
  • Abstract
  • Introduction
  • Pathology of pancreatic cancer
  • Molecular basis of pancreatic cancer
  • miRNAs in pancreatic cancer
  • Conclusion
  • References
  • Chapter 22: Extracellular vesicle-contained microRNAs in prostate cancer: From pathophysiology to emerging translational opportunities
  • Abstract
  • Overview
  • EV-contained miRNAs in PCa pathophysiology—What do we know so far?
  • Translational opportunities of EV-contained miRNAs for prostate cancer management
  • EV miRNAs in clinical practice—What do we still need to accomplish?
  • Funding
  • References
  • Chapter 23: Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma
  • Abstract
  • Introduction
  • Pathophysiology
  • MicroRNA deregulation in HCC
  • Diagnostic, prognostic, and predictive values of miRNAs
  • References
  • Chapter 24: Pathophysiology roles and translational opportunities of miRNAs in ovarian cancer
  • Abstract
  • Introduction
  • Pathophysiology
  • Extracellular miRNAs and prediction of treatment response
  • Concluding remarks
  • References
  • Chapter 25: Pathophysiology roles and translational opportunities of miRNAs in bladder cancer
  • Abstract
  • Bladder cancer epidemiology
  • Bladder cancer classification and diagnosis
  • MicroRNAs altered in BC and relevant for BC pathophysiology
  • MicroRNAs as diagnostic, prognostic, and predictive biomarkers
  • Circulating miRNAs in extracellular vesicles
  • Conclusions and perspectives
  • References
  • Chapter 26: Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma
  • Abstract
  • Cutaneous melanoma
  • MicroRNA
  • Circulating microRNAs as melanoma biomarkers
  • References
  • Chapter 27: Pathophysiology roles and translational opportunities of miRNAs in brain tumors
  • Abstract
  • Introduction
  • MiRNAs and perturbed cellular circuits in gliomas and glioblastomas
  • miRNAs and the glioma architecture
  • miRNAs and homotypic interactions between glioma cells
  • miRNAs and heterotypic interactions of gliomas and glioblastoma
  • Translating brain miRNAs in the clinical setting
  • References
  • Chapter 28: Pathophysiology roles and translational opportunities of miRNAs in sarcomas
  • Abstract
  • Acknowledgments
  • Introduction
  • Role of miRNAs in the pathogenesis and progression of bone sarcomas
  • Role of miRNAs in the pathogenesis and progression of soft tissue sarcomas
  • Circulating miRNAs in sarcoma
  • MiRNA and therapeutic approaches in sarcoma
  • Concluding remarks
  • References
  • Index

Product details

  • No. of pages: 432
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: February 17, 2022
  • Imprint: Academic Press
  • Paperback ISBN: 9780128222874
  • eBook ISBN: 9780128232743

About the Editors

Massimo Negrini

Massimo Negrini is an associate professor in Oncology at the University of Ferrara, where he teaches Molecular Oncology in different graduate and post-graduate programs. He is also director of the Specialization School in Oncology at the University of Ferrara and a biologist executive at the Hospital of Ferrara. He is editor-in-chief of the journal High-Throughput, an international, open access biomedical journal focused on the use of high-throughput technologies (microarray, NGS and other) and serves on the editorial boards of several other international biomedical journals focused on nucleic acids investigation. Prof. Negrini has co-authored more than 248 papers in international peer-reviewed journals.

Affiliations and Expertise

Professor of Medical Genetics, University of Ferrara, Ferrara, Italy

George Calin

George A. Calin received both his M.D. and Ph.D. degrees at Carol Davila University of Medicine in Bucharest, Romania. Since 2007, he has run an independent research group at the M. D. Anderson Cancer Center in Houston and produced a new advance by linking new classes of non-coding RNAs to cancer. He is presently a Professor in Experimental Therapeutics at MDACC and studies the roles of microRNAs (miRNAs) and other non-coding RNAs in cancer initiation and progression and in immune disorders, as well as the mechanisms of cancer predisposition linked to ncRNAs. Furthermore, he explores the roles of body fluids miRNAs as potential hormones and biomarkers, as well as new RNA therapeutic options for cancer patients. He has co-authored more than 400 papers and over 20 book chapters

Affiliations and Expertise

Professor in Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, TX, United States

Carlo Croce

Carlo M. Croce received his B.S. and M.D. degrees from University of Rome. In 1991, Dr. Croce was recruited as director of Kimmel Cancer Institute/Kimmel Cancer Center, Thomas Jefferson University. From 2004-2018, Dr. Croce served as John W. Wolfe Chair in Human Cancer Genetics, Chairman of the Department of Molecular Virology, Immunology and Medical Genetics, and Director of the Institute of Genetics, The Ohio State University (OSU). He is currently professor with the Department of Cancer Biology and Genetics at OSU. He has published more than 1,000 papers in international journals including Science, Nature, Cell, New Engl J Med, JAMA, and Cancer Cell. His research has yielded 62 issued U.S. patents. Dr. Croce is a member of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, The National Academy of Sciences, the Institute of Medicine, and AACR Academy.

Affiliations and Expertise

Professor of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States

Ratings and Reviews

Write a review

There are currently no reviews for "MicroRNA in Human Malignancies"